Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sreenivas Rao

Medical Oncology Florence, SC Medical Doctor

NPI 1942242102 CMS profile 224064

401 E Cheves St, Suite 201, Florence, SC 29506

Open in the dashboard

General payments

$4,420

177 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,975 paid to institutions, not to them · program year 2023

Through program year 2025, Sreenivas Rao of Florence, SC is reported in the CMS Open Payments database as having received $4,420 across 177 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,975 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 50th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,059 39
2024 General $895 39
2023 General $1,049 44
2022 General $849 29
2021 General $271 12
2020 General $119 3
2019 General $178 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sreenivas Rao
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Sreenivas Rao were reported at $1,059. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Sreenivas Rao Medical Oncology median Middle half National median
2019 $178 $968 $140–$6,658 $163
2020 $119 $747 $102–$5,891 $114
2021 $271 $430 $50–$4,098 $132
2022 $849 $812 $127–$4,907 $149
2023 $1,049 $957 $144–$5,248 $160
2024 $895 $1,042 $149–$5,650 $164
2025 $1,059 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $364 17 payments
  2. Novocure GmbH $250 1 payment
  3. Astellas Pharma US Inc $234 6 payments
  4. Amgen Inc. $218 10 payments
  5. Lilly USA, LLC $218 8 payments
  6. Celgene Corporation $217 12 payments
  7. Merck Sharp & Dohme Corporation $211 8 payments
  8. Seattle Genetics, Inc. $207 8 payments
  9. Janssen Biotech, Inc. $186 5 payments
  10. Genentech USA, Inc. $142 8 payments
  11. Other $2,172 94 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,687 169 payments
  2. Education $484 7 payments
  3. Honoraria $250 1 payment
Products named General payments · program years 2019–2025
  1. KISQALI $215 10 payments
  2. KEYTRUDA $198 7 payments
  3. DARZALEX $173 4 payments
  4. Pomalyst $147 8 payments
  5. Kyprolis $126 3 payments
  6. BRUKINSA $120 4 payments
  7. VENCLEXTA $109 2 payments
  8. Cook $109 1 payment
  9. Da Vinci Surgical System $102 1 payment
  10. XTANDI $99 5 payments
  11. Other $3,655 184 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

3,076

Median for Hematology-Oncology: 604

Drug cost

$12,473,845

Median for Hematology-Oncology: $1,306,514

Branded share of claims

33.6%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Revlimid Lenalidomide Brand 142 $2,545,712
Calquence Acalabrutinib Maleate Brand 86 $1,254,255
Lenalidomide Generic 101 $1,248,004
Imbruvica Ibrutinib Brand 78 $1,117,908
Xtandi Enzalutamide Brand 62 $849,401
Pomalyst Pomalidomide Brand 34 $770,627
Ibrance Palbociclib Brand 34 $585,821
Promacta Eltrombopag Olamine Brand 43 $579,804
Verzenio Abemaciclib Brand 36 $576,290
Abiraterone Acetate Generic 137 $411,022

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$103,206

Medicare's payments for the services billed

Medicare patients

420

Average age 75

Services billed

1,623

215 women, 205 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Cancer 48%
Chronic kidney disease 45%
Diabetes 43%
Ischemic heart disease 32%
COPD 29%
Heart failure 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $57
$57 — —
KISQALI
  • Novartis Pharmaceuticals Corporation $48
$48 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $43
$43 — —
VENCLEXTA
  • Genentech USA, Inc. $20
  • AbbVie, Inc. $14
$34 24 —
RYBREVANT
  • Janssen Biotech, Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record